ACAD
47.56
-1.19
-2.44%
AEMD
10
-1.38
-12.13%
APRI
1.52
-0.07
-4.40%
ARNA
3.99
-0.06
-1.48%
ATEC
1.37
+0.01
+0.74%
CNAT
4.9
-0.17
-3.35%
CRXM
0.295
0.00
0.00%
CYTX
0.4
-0.005
-1.3317%
DXCM
81.7
-1.39
-1.67%
GNMK
9.1
-0.66
-6.76%
HALO
22.8
-0.44
-1.89%
ILMN
217.27
-3.83
-1.73%
INNV
0.158
+0.008
+5.333%
INO
7.18
+0.12
+1.70%
ISCO
0.048
+0.004
+9.9537%
ISIS
53.68
+0.53
+1.00%
LGND
102.55
+0.46
+0.45%
LPTN
0.28
-0.02
-6.98%
MBVX
1.6
-0.19
-10.61%
MEIP
1.55
-0.06
-3.73%
MNOV
3.81
+0.3
+8.55%
MRTX
28.24
-0.48
-1.67%
MSTX
0.468
-0.002
-0.5106%
NBIX
49.34
-2.16
-4.19%
NUVA
49.59
+0.08
+0.16%
ONCS
6.03
-0.32
-5.04%
ONVO
3.38
-0.09
-2.59%
OREX
4.21
+0.02
+0.48%
OTIC
26.98
+0.32
+1.20%
QDEL
22.39
-0.5
-2.18%
RCPT
227.09
-0.91
-0.40%
RGLS
8.68
-0.49
-5.34%
RMD
55.17
-0.75
-1.34%
SCIE
0.019
-0.004
-16.300%
SPHS
0.86
+0.08
+10.26%
SRNE
23.7
+0.19
+0.81%
TROV
8.52
-0.28
-3.18%
VICL
0.61
-0.01
-2.40%
ZGNX
19.87
-0.4
-1.97%
ACAD
47.56
-1.19
-2.44%
AEMD
10
-1.38
-12.13%
APRI
1.52
-0.07
-4.40%
ARNA
3.99
-0.06
-1.48%
ATEC
1.37
+0.01
+0.74%
CNAT
4.9
-0.17
-3.35%
CRXM
0.295
0.00
0.00%
CYTX
0.4
-0.005
-1.3317%
DXCM
81.7
-1.39
-1.67%
GNMK
9.1
-0.66
-6.76%
HALO
22.8
-0.44
-1.89%
ILMN
217.27
-3.83
-1.73%
INNV
0.158
+0.008
+5.333%
INO
7.18
+0.12
+1.70%
ISCO
0.048
+0.004
+9.9537%
ISIS
53.68
+0.53
+1.00%
LGND
102.55
+0.46
+0.45%
LPTN
0.28
-0.02
-6.98%
MBVX
1.6
-0.19
-10.61%
MEIP
1.55
-0.06
-3.73%
MNOV
3.81
+0.3
+8.55%
MRTX
28.24
-0.48
-1.67%
MSTX
0.468
-0.002
-0.5106%
NBIX
49.34
-2.16
-4.19%
NUVA
49.59
+0.08
+0.16%
ONCS
6.03
-0.32
-5.04%
ONVO
3.38
-0.09
-2.59%
OREX
4.21
+0.02
+0.48%
OTIC
26.98
+0.32
+1.20%
QDEL
22.39
-0.5
-2.18%
RCPT
227.09
-0.91
-0.40%
RGLS
8.68
-0.49
-5.34%
RMD
55.17
-0.75
-1.34%
SCIE
0.019
-0.004
-16.300%
SPHS
0.86
+0.08
+10.26%
SRNE
23.7
+0.19
+0.81%
TROV
8.52
-0.28
-3.18%
VICL
0.61
-0.01
-2.40%
ZGNX
19.87
-0.4
-1.97%
Home » Archive by Category

Xconomy

At Acadia, “Mistakes Were Made,” A Drug Is Delayed & the CEO Is Out

March 11, 2015 – 4:06 pm

On Tuesday, Acadia Pharmaceuticals dropped out of two conferences and its stock price jumped, apparently because investors thought an acquisition was coming. Not quite. Instead San Diego-based Acadia…

[[Click headline to continue reading.]]

At Acadia, “Mistakes Were Made,” A Drug Is Delayed & the CEO Is Out

March 11, 2015 – 4:06 pm

On Tuesday, Acadia Pharmaceuticals dropped out of two conferences and its stock price jumped, apparently because investors thought an acquisition was coming. Not quite. Instead San Diego-based Acadia…

[[Click headline to continue reading.]]

In Move That Spells Relief, Zogenix Sells Painkiller to Pernix

March 10, 2015 – 6:50 pm

Zohydro was supposed to be a new kind of painkiller, but it gave Zogenix CEO Roger Hawley a headache that lasted more than a year. Now perhaps he can rest a little easier. After introducing Zohydro…

[[Click headline to continue reading.]]

In Move That Spells Relief, Zogenix Sells Painkiller to Pernix

March 10, 2015 – 6:50 pm

Zohydro was supposed to be a new kind of painkiller, but it gave Zogenix CEO Roger Hawley a headache that lasted more than a year. Now perhaps he can rest a little easier. After introducing Zohydro…

[[Click headline to continue reading.]]

Companion Diagnostic Specialist AltheaDx Withdraws IPO

March 10, 2015 – 8:20 am

San Diego’s AltheaDx, which offers a series of molecular diagnostic tests that enable doctors to identify the optimal drugs for treating patients, yesterday withdrew its plans for an initial public…

[[Click headline to continue reading.]]

NIH Director Hails “Stunning Case” as Example of Genomic Revolution

March 6, 2015 – 7:37 am

A pregnant mom who got a non-invasive prenatal test because she knew at age 40 that her baby was a higher risk for Down syndrome has become a case study in the potential power of precision medicine….

[[Click headline to continue reading.]]

NIH Director Hails “Stunning Case” as Example of Genomic Revolution

March 6, 2015 – 7:37 am

A pregnant mom who got a non-invasive prenatal test because she knew at age 40 that her baby was a higher risk for Down syndrome has become a case study in the potential power of precision medicine….

[[Click headline to continue reading.]]

West Coast Biotech Roundup: Pharmacyclics, Gates, Ikaria & More

March 5, 2015 – 3:01 pm

[Corrected 3/9/15, 11:46 pm. See below.] What a week for West Coast news, topped off by AbbVie’s surprise $21 billion grab of Pharmacyclics. It’s the ninth-largest biopharma acquisition…

[[Click headline to continue reading.]]

West Coast Biotech Roundup: Pharmacyclics, Gates, Ikaria & More

March 5, 2015 – 3:01 pm

[Corrected 3/9/15, 11:46 pm. See below.] What a week for West Coast news, topped off by AbbVie’s surprise $21 billion grab of Pharmacyclics. It’s the ninth-largest biopharma acquisition…

[[Click headline to continue reading.]]

With Narrowed Focus, Elcelyx Prepares for Diabetes Drug Trial

March 5, 2015 – 6:30 am

For San Diego’s Elcelyx Therapeutics, 2014 may someday be remembered as “the year of heavy lifting.” Since the fall of 2013, when Elcelyx spun out NaZura BioHealth as a sister company with the same…

[[Click headline to continue reading.]]